{"doi":"10.1007/s40265-024-02087-4","title":"Donanemab: First Approval","abstract":null,"journal":"Drugs","year":2024,"id":637152,"datarank":0.6476232170304466,"base_score":4.31748811353631,"endowment":4.31748811353631,"self_citation_contribution":0.6476232170304466,"citation_network_contribution":0.0,"self_endowment_contribution":0.6476232170304466,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":74,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":2,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1426230,"name":"Connie Kang","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Donanemab: First Approval","abstract":"Donanemab (donanemab-azbt; Kisunla<sup>TM</sup>) is an amyloid β-directed antibody developed by Eli Lilly and Company for the treatment of Alzheimer's disease. Donanemab recently received approval in the USA for the treatment of adults with early symptomatic Alzheimer's disease (patients with mild cognitive impairment or mild dementia stage of disease). This article summarizes the milestones in the development of donanemab leading to this first approval for Alzheimer's disease.","is_dataset_classified":null,"base_score":4.31748811353631,"endowment":4.31748811353631,"datacite_reuse_total":2,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"39237715","pmcid":null,"openalex_id":"https://openalex.org/W4402321957","authors":[],"funders":[],"total_grants":0,"fwci":36.5404,"citation_percentile":0.99928293,"influential_citations":1,"citation_trend":[{"year":2024,"count":5},{"year":2025,"count":41},{"year":2026,"count":28}],"oa_status":"closed","license":"https://www.springernature.com/gp/researchers/text-and-data-mining","oa_locations":[{"url":"https://figshare.com/articles/online_resource/Donanemab_First_Approval/26409457/1/files/48868348.pdf","host_type":"GREEN"},{"url":"https://link.springer.com/content/pdf/10.1007/s40265-024-02087-4.pdf","host_type":"publisher"},{"url":"https://link.springer.com/article/10.1007/s40265-024-02087-4/fulltext.html","host_type":"publisher"},{"url":"https://doi.org/10.1007/s40265-024-02087-4","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/39237715","host_type":"repository"}],"fields_of_study":["Psychiatric care and mental health services","Medicine","Humans","Alzheimer Disease","Drug Approval","Antibodies, Monoclonal, Humanized","Amyloid beta-Peptides","United States","Cognitive Dysfunction","United States Food and Drug Administration"],"mesh_terms":["Alzheimer Disease","Humans","United States","United States Food and Drug Administration","Amyloid beta-Peptides","Drug Approval","Cognitive Dysfunction","Antibodies, Monoclonal, Humanized"],"keywords":["Medicine","Pharmacotherapy","Intensive care medicine","Medical physics","Pharmacology","Internal medicine"],"sdg_mappings":[],"linked_datasets":[{"doi":"10.6084/m9.figshare.26409457.v1","title":"Donanemab: First Approval","publisher":"Adis Journals","resource_type":"Other"},{"doi":"10.6084/m9.figshare.26409457","title":"Donanemab: First Approval","publisher":"Adis Journals","resource_type":"Other"}],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-06T18:25:26.248972Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}